EF
AZN icon

Exeter Financial’s AstraZeneca AZN Stock Holding History

Exeter Financial’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,025
Closed -$202K – 102
2026
Q1 		$202K Buy
+1,025
New +$198K 0.08% 97

Other funds holding AZN

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
BTCPP
Border to Coast Pensions Partnership Leeds, United Kingdom $6.78B AUM 31.6% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Exeter Financial's AZN Position: Q2 2026 in Review

Exeter Financial sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 1,025 shares — an estimated $202K sold.

Exeter Financial first reported a position in AZN in Q1 2026 and held it in 1 quarter. The position peaked at $202K in Q1 2026. 539 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Exeter Financial reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
  • Exeter Financial sold 1,025 AstraZeneca shares in Q2 2026, an estimated $202K.
  • Exeter Financial first reported a position in AstraZeneca in Q1 2026 and held it in 1 quarter.
  • Exeter Financial's AstraZeneca position peaked at $202K in Q1 2026.
  • 539 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Exeter Financial's 13F filing for Q2 2026, filed 16 Jul 2026.